Moderna is developing mRNA vaccines for endemic human coronavirus
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
Moderna is developing mRNA vaccines for endemic human coronavirus
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Moderna is developing mRNA vaccines for endemic human coronavirus.
On March 25, Moderna announced at its third annual Vaccine Day that it is preparing to develop a vaccine candidate (mRNA-1287) against the endemic human coronavirus (HCoV).
It targets four coronaviruses: HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
These 4 coronaviruses are not unpredictable and destructive in human impact and usually only cause common colds and upper respiratory tract infections.
But for some high-risk groups (such as the elderly), viral infections can also lead to further severe illness, such as secondary bacterial infections and pneumonia.
Globally, 10%-30% of upper respiratory tract infections are caused by the above four viruses, which are the second most common cause of common cold after rhinovirus.
“It would be a good idea to develop this vaccine if it could induce protection in high-risk individuals, especially against seasonal respiratory viruses,” said former FDA acting chief scientist Luciana Borio.
Moderna didn’t share many details about its mRNA-1287 vaccine candidate and didn’t respond to a request for comment, but the vaccine will likely be administered intramuscularly like other vaccines.
However, data from the mRNA Covid-19 vaccine show that intramuscular injection does not provide the durable protection against coronavirus infection and symptomatic disease that is hoped for in a common cold vaccine.
Moderna is developing mRNA vaccines for endemic human coronavirus
(source:internet, reference only)
Disclaimer of medicaltrend.org
